Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Acta pediatr. esp ; 71(8): e224-e232, sept. 2013. tab, ilus
Article in Spanish | IBECS | ID: ibc-116759

ABSTRACT

Introducción: Las malformaciones congénitas pulmonares (MCP) son infrecuentes y generalmente cursan de forma asintomática en el periodo neonatal. Actualmente, su detección se realiza mediante estudios antenatales, confirmándose en el momento del nacimiento mediante pruebas de imagen. Aunque puede mantenerse una actitud expectante en los pacientes asintomáticos, es recomendable realizar una cirugía programada a los 3-6 meses de vida, dadas las graves complicaciones que pueden presentar estos pacientes. Casos clínicos: Presentamos 4 casos de MCP detectados antenatalmente en nuestro centro en los últimos 6 años, valorando su diagnóstico, características y evolución posterior. Resultados: Los 4 casos fueron malformaciones unilaterales detectadas antenatalmente mediante la ecografía del segundo trimestre, y en 3 de ellos también por resonancia magnética. Uno de ellos es una lesión híbrida, malformación adenomatoidea pulmonar congénita asociada a un secuestro intralobar en el pulmón contralateral. En el momento del nacimiento sólo 1 paciente presentó dificultad respiratoria; los otros estaban asintomáticos. La radiografía simple y la tomografía computarizada (TC) realizadas posnatalmente confirmaron el diagnóstico en 3 pacientes, pero en 1 la radiografía fue normal y la TC posterior demuestra una lesión compatible con atresia bronquial. Se realizó una lobectomía del paciente con dificultad respiratoria neonatal y del paciente con MCP-secuestro, que había presentado una infección pulmonar a los 3 meses. Conclusiones: Nuestra serie aporta 4 casos de excepcional observación. Al tratarse de una patología potencialmente grave, es importante que la conozcan todos los pediatras, así como una implicación multidisciplinaria que permita unificar criterios para proporcionar el mejor manejo posible a nuestros pacientes (AU)


Introduction: Congenital lung malformations are rare and generally have an asymptomatic development in the neonatal period. The detection of this condition is done by antenatal studies and it is later confirmed at birth with imaging tests. Although an expectant attitude towards asymptomatic patients may be adopted, the recommendation is to perform a surgical resection programmed between 3-6 months of life, given the serious complications these patients can suffer. Clinical cases: This study presents 4 cases of congenital lung malformations –detected antenatally in our center in the last 6 years– focusing on their diagnosis, characteristics and further development. Results: All four cases were unilateral malformations detected antenatally by the second quarter ultrasound, of which three were also detected by nuclear magnetic resonance. One of them was a hybrid lesion (congenital malformation of the lung-pulmonary sequestration) associated with an intralobar sequestration in the contralateral lung. Only one of the cases presented respiratory distress at birth, the others being asymptomatic. The chest-X-ray and axial tomography (CT) done postnatally confirmed the diagnosis in three of the patients; the fourth patient was diagnosed after a CT showed bronchial atresia, despite having a normal chest-X-ray. Lobectomy was performed on the patient with neonatal distress and the patient with the hybrid lesion, who had had a pulmonary infection at 3 months of life. Conclusions: This study provides 4 cases of exceptional observation. Congenital lung malformation is a potentially serious pathology, so it is important for all pediatricians to know about it. Thus, a multidisciplinary involvement is needed so as to unify criteria in order to provide patients with the best specialised care (AU)


Subject(s)
Humans , Male , Female , Infant, Newborn , Lung/abnormalities , Respiratory System Abnormalities/epidemiology , Prenatal Diagnosis/methods , Diagnostic Imaging , Radiography, Thoracic , Tomography , Ultrasonography, Prenatal
4.
An Pediatr (Barc) ; 69(3): 239-43, 2008 Sep.
Article in Spanish | MEDLINE | ID: mdl-18775269

ABSTRACT

INTRODUCTION: Glutaric Acidaemia type I (GA-I) is an autosomal recessive progressive neurodegenerative inborn error of metabolism caused by deficient activity of the enzyme glutaryl-CoA dehydrogenase (GCDH). In most cases, the diagnosis is established biochemically by the detection of glutaric acid and 3-hydroxy glutaric acid in urine and glutarylcarnitine in plasma. Patients excreting small amounts of glutaric acid may be overlooked. OBJECTIVE: To investigate the value of expanded newborn screening by adding the measurement of urine glutarylcarnitine to conventional chromatography-mass spectrometry (GC-MS) in the diagnosis of GA-1. MATERIAL AND METHODS: We report clinical and biochemical data in 5 GA-I patients diagnosed in our Hospital. Details regarding biochemical diagnosis are emphasised and the absence or presence of symptoms was correlated with neuroimaging findings, age at diagnosis and treatment. RESULTS: Two patients showed high glutarylcarnitine levels in plasma and were identified by routine newborn GC-MS screening. Following early appropriate treatment they are asymptomatic 6 years later. Two patients with delayed diagnosis displayed neurological sequels in spite of treatment. The remaining patient, who presented with encephalopathic episode at age 8 months showed normal glutarylcarnitine levels in routine plasma GC-MS but high urine glutarylcarnitine levels in a retrospectively screened urine sample from the newborn period. CONCLUSIONS: Early treatment seems to positively influence the clinical evolution of GA-I patients. Thus, improving the identification of GA-I represents an important diagnostic challenge. The urinary excretion of glutarylcarnitine is a specific biochemical marker of GA-I and allows the identification of patients without glutaric aciduria and with normal plasma acylcarnitine profiles.


Subject(s)
Amino Acid Metabolism, Inborn Errors/diagnosis , Amino Acid Metabolism, Inborn Errors/therapy , Glutarates/blood , Early Diagnosis , Female , Humans , Infant, Newborn , Male , Prognosis
5.
An. pediatr. (2003, Ed. impr.) ; 69(3): 239-243, sept. 2008. tab
Article in Es | IBECS | ID: ibc-67456

ABSTRACT

Introducción. La aciduria glutárica tipo I (AG-I) es un desorden metabólico de herencia autosómica recesiva y carácter progresivo debido al déficit de la enzima glutaril-CoA-deshidrogenasa (GCDH). El diagnóstico se realiza generalmente por una elevación del ácido glutárico y 3-hidroxiglutárico en la orina y de la glutarilcarnitina en el plasma. Existen casos falsos negativos en relación con la baja tasa excretora del ácido glutárico. Objetivo. Resaltar la importancia de la ampliación del cribado neonatal por espectrofotometría de masas en tándem (MS/MS) mediante la inclusión de la medición de glutarilcarnitina en la orina para su diagnóstico. Material y métodos. Se aportan los datos clínicos y el perfil bioquímico que llevaron al diagnóstico en 5 pacientes diagnosticados de AG-I en nuestro centro. Se analiza la evolución clínica y de neuroimagen en función de la edad, el diagnóstico y el inicio del tratamiento. Resultados. Dos casos de diagnóstico por cribado convencional mediante MS/MS siguieron un tratamiento precoz y están asintomáticos 6 años después. Dos pacientes de diagnóstico y tratamiento tardíos presentan secuelas neurológicas. El último paciente, diagnosticado a los 8 meses tras una presentación aguda encefalopática, mostraba valores de glutarilcarnitina en plasma en rango normal, mientras que el análisis retrospectivo de la orina del período neonatal reveló valores elevados de glutarilcarnitina. Conclusiones. El tratamiento temprano parece asociarse a una evolución neurológica favorable en pacientes con AG-I, por lo que su identificación precoz constituye un reto diagnóstico. La excreción urinaria de glutarilcarnitina es un marcador específico de AG-I y permite la identificación de pacientes sin aciduria glutárica y valores normales de glutarilcarnitina en sangre


Introduction. Glutaric Acidaemia type I (GA-I) is an autosomal recessive progressive neurodegenerative inborn error of metabolism caused by deficient activity of the enzyme glutaryl-CoA dehydrogenase (GCDH). In most cases, the diagnosis is established biochemically by the detection of glutaric acid and 3-hydroxy glutaric acid in urine and glutarylcarnitine in plasma. Patients excreting small amounts of glutaric acid may be overlooked. Objective. To investigate the value of expanded newborn screening by adding the measurement of urine glutarylcarnitine to conventional chromatography-mass spectrometry (GC-MS) in the diagnosis of GA-1. Material and methods. We report clinical and biochemical data in 5 GA-I patients diagnosed in our Hospital. Details regarding biochemical diagnosis are emphasised and the absence or presence of symptoms was correlated with neuroimaging findings, age at diagnosis and treatment. Results. Two patients showed high glutarylcarnitine levels in plasma and were identified by routine newborn GC-MS screening. Following early appropriate treatment they are asymptomatic 6 years later. Two patients with delayed diagnosis displayed neurological sequels in spite of treatment. The remaining patient, who presented with encephalopathic episode at age 8 months showed normal glutarylcarnitine levels in routine plasma GC-MS but high urine glutarylcarnitine levels in a retrospectively screened urine sample from the newborn period. Conclusions. Early treatment seems to positively influence the clinical evolution of GA-I patients. Thus, improving the identification of GA-I represents an important diagnostic challenge. The urinary excretion of glutarylcarnitine is a specific biochemical marker of GA-I and allows the identification of patients without glutaric aciduria and with normal plasma acylcarnitine profiles


Subject(s)
Humans , Male , Female , Infant , Child , Adolescent , Metabolic Diseases/diagnosis , Metabolic Diseases/therapy , Early Diagnosis , Glutamic Acid/metabolism , Mass Screening , Prognosis
8.
Rev Neurol ; 28(9): 881-2, 1999.
Article in Spanish | MEDLINE | ID: mdl-10390753

ABSTRACT

INTRODUCTION: Neurological disorders secondary to the measles component of viral triple vaccine are not frequent. In spite of controversy regarding the cause, the clinical, diagnostic and legal implications are worth considering. CLINICAL CASE: We present the case of a 16 month-old baby with a clinical picture of self-limiting acute encephalopathy characterized by cerebellar ataxia and alterations in behavior, accompanied by the clinical signs of attenuated measles. The negative results of complementary tests and an obvious time-relationship with a triple virus vaccination lead us to interpret the condition as being secondary to the measles component of the vaccine. CONCLUSIONS: We consider that although there is a low incidence of complications, the index of suspicion is also low, and even lower in cases with only minor neurological signs. It is therefore possible that such reactions are under-reported.


Subject(s)
Encephalitis, Viral/etiology , Measles Vaccine/adverse effects , Vaccination/adverse effects , Vaccines, Combined , Acute Disease , Encephalitis, Viral/immunology , Humans , Immunoglobulin M/immunology , Infant , Male , Measles Vaccine/immunology
9.
Rev Neurol ; 29(10): 912-7, 1999.
Article in Spanish | MEDLINE | ID: mdl-10637838

ABSTRACT

INTRODUCTION: Complex IV or cytochrome c oxidase (COX) deficiency is the most common disorder involving complexes of the respiratory chain in the pediatric age. Exceptionally, it has been reported in association with Alpers syndrome or Alpers disease, and with its variant named progressive neuronal degeneration with liver disease or Alpers-Huttenlocher syndrome. OBJECTIVE: To report the cases of two infants with mitochondrial encephalomyopathy due to COX deficiency in whom the clinical, biochemical, neurophysiologic and neuroimaging characterization suggested an associated Alpers-Huttenlocher syndrome. CLINICAL CASES: Two no-related males, one with noncontributory family history and the other with third-grade consanguineous parents developed refractory seizures from age 20 and 60 days, respectively. Additionally, myoclonic fits accounted on evolution of the condition. In the first case, serial EEG recordings showed low amplitude polyspikes, polyspike waves and very slow waves of high amplitude alternating with a trace of burst-suppression activity. In the second case, a right preponderant but also bilateral low amplitude polyspikes, polyspike waves and occasional desynchronization of basal trace were recorded. In both, a rapidly progressive cerebral atrophy, neurological deterioration with pyramidal signs, and tendency to microcephaly, ensued. Accompanying to this clinical picture, minor hepatic dysfunction, elevated protein levels in the CSF, lactic acidosis and COX deficiency in muscle homogenate were demonstrated. In the first case, moreover, cortical blindness and severe hepatic failure occurred while receiving valproate, in spite of concomitant L-carnitine therapy. CONCLUSIONS: We believe that the reported cases are consisted with Alpers-Huttenlocher syndrome associated with mitochondrial encephalomyopathy due to COX deficiency. Nevertheless, early myoclonic encephalopathy, a condition related in same cases with poliodistrophy, must be keep in mind as a possible diagnosis in case 1.


Subject(s)
Cytochrome-c Oxidase Deficiency , Diffuse Cerebral Sclerosis of Schilder/diagnosis , Leigh Disease/complications , Leigh Disease/diagnosis , Mitochondrial Encephalomyopathies/etiology , Anticonvulsants/adverse effects , Atrophy/pathology , Cerebral Cortex/pathology , Cerebrospinal Fluid Proteins/analysis , Diagnosis, Differential , Disease Progression , Electroencephalography , Humans , Infant , Liver Failure/chemically induced , Magnetic Resonance Imaging , Male , Seizures/complications , Seizures/drug therapy , Valproic Acid/adverse effects
11.
Rev Neurol ; 23(122): 769-72, 1995.
Article in Spanish | MEDLINE | ID: mdl-7497237

ABSTRACT

A retrospective study of 101 cases of infantile migraine aged between 3 and 14 years is reported. Both sexes were affected equally, being common migraine the most frequent form. The immediate positive family history for migraine and underlying precipitating factors were identified in 66% and 88% of the cases respectively. The electroencephalographic picture displayed focal spike and wave or sharp and slow wave discharges in 19.1% of the cases. The evolution was favourable in 92% and there was no correlated with headache frequency or treatment approach. The better therapeutic response was obtained when underlying precipitating factors were removed. The most effective prophylactic drugs in our series were flunarizine, propanolol and dimetotiazine. We discuss the most relevant features of the migraine in the infancy.


Subject(s)
Calcium Channel Blockers/therapeutic use , Flunarizine/therapeutic use , Headache/drug therapy , Migraine Disorders/drug therapy , Phenothiazines/therapeutic use , Propranolol/therapeutic use , Calcium Channel Blockers/administration & dosage , Child , Female , Flunarizine/administration & dosage , Headache/prevention & control , Humans , Male , Migraine Disorders/prevention & control , Phenothiazines/administration & dosage , Propranolol/administration & dosage , Retrospective Studies
12.
J Pediatr ; 126(6): 965-7, 1995 Jun.
Article in English | MEDLINE | ID: mdl-7776109

ABSTRACT

A 15-day-old girl was found to have generalized gastrointestinal polyposis resulting from Peutz-Jeghers syndrome. Her manifestations included abdominal distention, hematemesis, bloody diarrhea, and edema. She died at 1 year of age of multiple complications of her disease.


Subject(s)
Peutz-Jeghers Syndrome/pathology , Female , Humans , Infant , Infant, Newborn
SELECTION OF CITATIONS
SEARCH DETAIL
...